Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The selected QUZYTTIR IV label does not require a renal dose change in the stated populations, but use below age 6 with renal or hepatic impairment is not recommended. Oral levocetirizine has a separate renal schedule and exclusions.
Before applying: Match the ingredient, route, age and acute-urticaria indication. Do not transfer an oral schedule to this IV product or turn a pediatric not-recommended statement into an adult contraindication.
Also check: IV cetirizine is not the oral levocetirizine renal schedule
Official source
QUZYTTIR - IV cetirizine, renal and age-specific instructions
Product / population
QUZYTTIR IV cetirizine for acute urticaria. Renal guidance applies with the explicit under-6-year exclusion.
Renal measure
Label categorical renal impairment and dialysis; no quantitative threshold assigned here.
Renal dosing, restrictions and evidence limits
The March 2026 label requires no dose adjustment for moderate or severe renal impairment or dialysis, with monitoring for antihistaminic adverse effects. This does not override the statement that use is not recommended below age 6 with impaired renal or hepatic function. For acute urticaria, patients >=12 years receive 10 mg IV; ages 6-11 receive 5 or 10 mg according to symptom severity. Give over 1-2 minutes, once every 24 hours as needed. These are IV product instructions; oral cetirizine and oral levocetirizine renal schedules must not be substituted. Dialysis does not effectively remove cetirizine in overdose.
Source revision: March 2026 | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
formulation and population
IV cetirizine is not the oral levocetirizine renal schedule
The selected QUZYTTIR IV label does not require a renal dose change in the stated populations, but use below age 6 with renal or hepatic impairment is not recommended. Oral levocetirizine has a separate renal schedule and exclusions.
How to use this: Match the ingredient, route, age and acute-urticaria indication. Do not transfer an oral schedule to this IV product or turn a pediatric not-recommended statement into an adult contraindication.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
QUZYTTIR - IV cetirizine, renal and age-specific instructions
QUZYTTIR IV cetirizine for acute urticaria. Renal guidance applies with the explicit under-6-year exclusion.
Method: Label categorical renal impairment and dialysis; no quantitative threshold assigned here.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed · QUZYTTIR IV cetirizine for acute urticaria. Renal guidance applies with the explicit under-6-year exclusion.
Renal method: Label categorical renal impairment and dialysis; no quantitative threshold assigned here. Source date: March 2026 Retrieved: 2026-09-07
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The March 2026 label requires no dose adjustment for moderate or severe renal impairment or dialysis, with monitoring for antihistaminic adverse effects. This does not override the statement that use is not recommended below age 6 with impaired renal or hepatic function. For acute urticaria, patients >=12 years receive 10 mg IV; ages 6-11 receive 5 or 10 mg according to symptom severity. Give over 1-2 minutes, once every 24 hours as needed. These are IV product instructions; oral cetirizine and oral levocetirizine renal schedules must not be substituted. Dialysis does not effectively remove cetirizine in overdose.
RDM35-official-cetirizine-quzyttir-iv-0e5c33e7b2-C1 · Source locator: Sections 1, 2.1-2.3, 8.4, 8.7 and 10; full prescribing information.
GlobalRPh-hosted RX List · QUZYTTIR intravenous cetirizine; oral-study findings are supporting evidence only.
Renal method: CrCl, mL/min, in oral studies; no IV renal-dose method established. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
IV cetirizine pharmacokinetics were not evaluated in renal impairment. Supporting oral-cetirizine studies showed reduced clearance in moderate impairment and in hemodialysis patients, but those oral findings are not an IV renal dosing algorithm. No numerical IV adjustment is established by the selected pharmacokinetic section; obtain complete current IV product guidance before prescribing.
RDM34-rxlist-quzyttir-drug-C1 · Source locator: Clinical pharmacology: patients with renal impairment.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.